Haemonetics (NYSE:HAE) Shares Down 5.6% – Here’s What Happened

Shares of Haemonetics Corporation (NYSE:HAE) fell 5.6% during trading on Friday . The company traded as low as $60.32 and last traded at $61.4050. 451,712 shares changed hands during trading, a decline of 48% from the average session volume of 861,341 shares. The stock had previously closed at $65.02.

More Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Q3 results beat consensus: HAE reported $1.31 EPS vs. $1.27 expected and revenue of $338.97M vs. ~$331.9M, with margins improving—evidence of profitable execution. Haemonetics (HAE) Q3 Earnings and Revenues Beat Estimates
• Positive Sentiment: Company raised FY‑2026 outlook and signaled strong organic growth (management highlighted plasma and blood‑management strength and an 8%–10% organic growth outlook), which supports longer‑term revenue momentum. Haemonetics raises fiscal 2026 guidance as plasma and blood management drive 8%-10% organic growth outlook
• Positive Sentiment: Analyst support remains: BTIG reaffirmed a “buy” and a $88 price target, indicating continued analyst conviction above current levels. Benzinga coverage of BTIG rating
• Neutral Sentiment: Investor materials and transparency: the company posted its press release, slide deck and earnings‑call transcript for review—useful for digging into segment trends and guidance detail. PR Newswire: Q3 financial results available
• Neutral Sentiment: Zacks highlights HAE as a top‑ranked growth stock by style scores—an informational signal for growth‑oriented investors but not an immediate price catalyst. Haemonetics (HAE) is a Top-Ranked Growth Stock: Should You Buy?
• Negative Sentiment: Revenue weakness and mixed investor reaction: revenue fell ~2.7% YoY despite the beat, and the market reacted negatively (shares slipped after the report)—suggesting investors wanted stronger top‑line improvement or more aggressive guidance. Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips

Analyst Ratings Changes

Several equities research analysts have commented on the company. BTIG Research reiterated a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a research note on Friday. Weiss Ratings reiterated a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 29th. Robert W. Baird set a $81.00 price objective on Haemonetics in a report on Friday. Barrington Research set a $94.00 target price on shares of Haemonetics in a report on Friday. Finally, CJS Securities upgraded shares of Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $84.44.

Haemonetics Stock Down 8.7%

The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.03 and a current ratio of 1.75. The business has a 50 day simple moving average of $76.84 and a 200-day simple moving average of $65.11. The firm has a market capitalization of $2.78 billion, a price-to-earnings ratio of 16.35, a P/E/G ratio of 1.23 and a beta of 0.28.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The firm had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. During the same quarter in the prior year, the firm posted $1.19 earnings per share. Haemonetics’s quarterly revenue was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. On average, equities analysts expect that Haemonetics Corporation will post 4.55 EPS for the current year.

Institutional Investors Weigh In On Haemonetics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its holdings in shares of Haemonetics by 372.8% during the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after purchasing an additional 1,678,630 shares during the period. Millennium Management LLC boosted its stake in Haemonetics by 4,296.3% during the third quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock worth $37,685,000 after buying an additional 755,592 shares during the period. Norges Bank acquired a new stake in shares of Haemonetics during the second quarter valued at about $36,822,000. Invenomic Capital Management LP raised its stake in shares of Haemonetics by 1,691.5% in the 3rd quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock valued at $24,288,000 after acquiring an additional 470,502 shares during the period. Finally, SG Capital Management LLC raised its stake in shares of Haemonetics by 92.5% in the 2nd quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock valued at $67,663,000 after acquiring an additional 435,660 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.